



CLAIMS






1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,



wherein

n is 2-20;


Q¹ is a bond or , wherein m is 0-100;


L is , , , , or , wherein R^x is H or halogen;

Q² is a bond or a self-immolative spacer; and

Z is an anti-cancer drug.



2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

Q¹ is a bond or .



3. The compound of any one of claims 1-2, or a pharmaceutically acceptable salt thereof, wherein Z is a polo-like kinase 1 (PLK-1) inhibitor, a tubulin polymerase inhibitor, a tubulin stabilizer, an antineoplastic agent, an eukaryotic translation initiation factor 4 (EIF4) inhibitor, a combretastatin A-4 analog, or a flavagline analog.

4. The compound of any one of claims 1-3, having a structure of formula (I-a), or a pharmaceutically acceptable salt thereof, wherein




and

Z is a PLK-1 inhibitor, a tubulin polymerase inhibitor, a tubulin stabilizer, an antineoplastic agent, or an eukaryotic translation initiation factor 4 (EIF4) inhibitor.

5. The compound of claim 4, wherein Z is a PLK-1 inhibitor or an antineoplastic agent selected from the group consisting of monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), and monomethyl auristatin E (MMAD).

6. The compound of any one of claims 1-3, having a structure of formula (I-b), or a pharmaceutically acceptable salt thereof, wherein


n is 18;



Z is a combretastatin A-4 analog.





7. The compound of any one of claims 1-3, having a structure of formula (I-c), or a pharmaceutically acceptable salt thereof, wherein


n is 18;




Z is a flavagline analog.

8. The compound of claim 1, which is selected from the group consisting of







(CLR2013),




(CLR2000045),




(CLR2010),



(CLR180095),



(CLR1800099A), and



(CLR1800099B),

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
10. A method of treating cancer in a subject in need thereof, comprising administering an effective amount of a compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof.
11. The method of claim 10, wherein the cancer is melanoma, lung cancer, colorectal cancer, breast cancer, or a combination thereof.
12. The method of any one of claims 10-11, wherein
the lung cancer comprises small cell lung cancer, non-small cell lung cancer, or a combination thereof;

the melanoma comprises superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma, nevoid melanoma, spitzoid melanoma, desmoplastic melanoma, or a combination thereof;

the colorectal cancer comprises adenocarcinoma; or

the breast cancer comprises invasive breast ductal carcinoma, metastatic breast cancer, inflammatory breast cancer, triple negative breast cancer, ductal carcinoma in situ, or a combination thereof.

13. The method of any one of claims 10-12, wherein the cancer comprises cancer stem cells.

14. The method of any one of claims 10-13, wherein the cancer comprises metastatic cancer cells

15. The method of any one of claims 10-14, wherein the cancer comprises circulating tumor cells.

16. The method of any one of claims 10-15, wherein the cancer is melanoma, lung cancer, colorectal cancer, or a combination thereof, and wherein the compound is a compound of formula (I-a), or a pharmaceutically acceptable salt thereof.

17. The method of any one of claims 10-15, wherein the cancer is breast cancer, wherein the subject (1) is estrogen receptor positive, (2) is both estrogen receptor negative and progesterone receptor negative, (3) expresses HER2 (HER2+), (4) does not express HER2 (HER2-), or a combination thereof.

18. The method of any one of claims 10-15 and 17, wherein the cancer is breast cancer, and wherein the compound is a compound of formula (I-b), or a pharmaceutically acceptable salt thereof.

19. The method of any one of claims 10-15, wherein the cancer is cancer is melanoma, lung cancer, colorectal cancer, breast cancer, or a combination thereof, and wherein the compound is a compound of formula (I-c), or a pharmaceutically acceptable salt thereof.